Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.44 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | CCR8 | P51685 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24675012 | 0.96 | CYP1A2 (0.50) | CYP2A6CYP1A2PSMD14COPS5HTT | |
| SCHEMBL51697 | 0.78 | IDO1 (0.46) | CYP1A2ALDH1A1ADRA1AL3MBTL1MAPT | |
| SCHEMBL8404538 | 0.78 | CYP2A6 (0.59) | CYP2A6CYP1A2PSMD14COPS5HTT | |
| SCHEMBL29478202 | 0.78 | IDO1 (0.46) | CYP1A2ALDH1A1ADRA1AL3MBTL1MAPT | |
| SCHEMBL22627556 | 0.76 | HTR1A (0.36) | CYP2A6CYP1A2PSMD14COPS5HTT | |
| SCHEMBL20470726 | 0.75 | CYP1A2 (0.54) | CYP2A6CYP1A2PSMD14COPS5HTT | |
| SCHEMBL1536453 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2PSMD14COPS5HTT | |
| SCHEMBL16006827 | 0.75 | CYP1A2 (0.54) | CYP2A6CYP1A2PSMD14COPS5ALDH1A1 | |
| SCHEMBL12055258 | 0.75 | KDM4E (0.44) | ALDH1A1L3MBTL1MAPTLMNAKDM4E | |
| SCHEMBL540013 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2PSMD14COPS5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338486-B2 | Single-stranded break detection in double-stranded DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-06-24 | — | — | US | claimed |
| EP-3781711-B1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INST TECHNOLOGY (US) | 2024-11-20 | — | — | EP | claimed |
| US-11505827-B2 | Systems and methods for determining genetic data | Roche Sequencing Solutions, Inc. (US) | 2022-11-22 | — | — | US | claimed |
| US-20210071240-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-03-11 | — | — | US | claimed |
| EP-3781711-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-24 | — | — | EP | claimed |
| WO-2019204585-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-10-24 | — | — | WO | claimed |
| US-20190292591-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2019-09-26 | — | — | US | claimed |
| US-10260093-B2 | Systems and methods for determining genetic data | Genia Technologies, Inc. (US) | 2019-04-16 | — | — | US | claimed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| US-20140303032-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Roche Sequencing Solutions, Inc. | 2014-10-09 | — | — | US | claimed |
| WO-2013067208-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2013-05-10 | — | — | WO | claimed |
| EP-1373561-B1 | USE OF MASS-MATCHED NUCLEOTIDES IN THE ANALYSIS OF OLIGONUCLEOTIDE MIXTURES AND IN HIGHLY MULTIPLEXED NUCLEIC ACID SEQUENCING | UNIV BOSTON (US) | 2009-02-18 | — | — | EP | claimed |
| US-7374882-B2 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2008-05-20 | — | — | US | claimed |
| US-20040115665-A1 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2004-06-17 | — | — | US | claimed |
| JP-2004514440-A | — | — | 2004-05-20 | — | — | JP | claimed |
| US-20040077004-A1 | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and highly multiplexed nucleic acid sequencing | TRUSTEES OF BOSTON UNIVERSITY, THE | 2004-04-22 | — | — | US | claimed |
| US-6660229-B2 | Synthesizing extension products of the target nucleic acid in the presence of chain terminating nucleotides and mass-matched nucleotides; determining the mass of each extension product; and calculating a mass shift | THE TRUSTEES OF BOSTON UNIVERSITY | 2003-12-09 | — | — | US | claimed |
| EP-1348035-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | Riken (JP) | 2003-10-01 | — | — | EP | claimed |
| WO-2002044195-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | RIKEN (JP) | 2002-06-06 | — | — | WO | claimed |
| US-20260110026-A1 | METHODS FOR PROPAGATING AND MAPPING LOCATION OF NON-NATURAL BASES | ILLUMINA, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4719437-A1 | CONNECTOR MODIFIED SYNTHETIC RIG-I AGONISTS AND METHODS OF USING THE SAME | RIGImmune Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250388955-A1 | METHYLATION DETECTION WITH A NON-NATURAL/UNNATURAL BASE | ILLUMINA INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4574993-A2 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338486-B2 | Single-stranded break detection in double-stranded DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250157582-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-3540076-B1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3733875-B1 | METHOD FOR ASSEMBLING A PROTEIN | ROCHE SEQUENCING SOLUTIONS INC (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024243293-A1 | CONNECTOR MODIFIED SYNTHETIC RIG-I AGONISTS AND METHODS OF USING THE SAME | RIGIMMUNE INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| EP-3781711-B1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INST TECHNOLOGY (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024006783-A2 | METHYLATION DETECTION WITH A NON-NATURAL/UNNATURAL BASE | ILLUMINA, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4276194-A2 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3978621-B1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11674174-B2 | Nucleic acid sequences using tags | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-13 | — | — | US | disclosed |
| US-11505827-B2 | Systems and methods for determining genetic data | Roche Sequencing Solutions, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11499190-B2 | Nucleic acid sequencing using tags | Roche Sequencing Solutions, Inc. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220205037-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | SEQUENOM, INC. | 2022-06-30 | — | — | US | disclosed |
| US-11306354-B2 | Methods and compositions for analyzing nucleic acid | SEQUENOM, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3978621-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3663409-B1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210071240-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-03-11 | — | — | US | disclosed |
| EP-3781711-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200407786-A1 | NUCLEIC ACID SEQUENCING USING TAGS | ROCHE SEQUENCING SOLUTIONS INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200377944-A1 | COMPOSITIONS AND METHODS FOR UNIDIRECTIONAL NUCLEIC ACID SEQUENCING | ROCHE SEQUENCING SOLUTIONS INC (US) | 2020-12-03 | — | — | US | disclosed |
| EP-3733874-A1 | UNIDIRECTIONAL SEQUENCING USING PANDOMERS | Genia Technologies, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733875-A1 | METHOD FOR ASSEMBLING A PROTEIN | Genia Technologies, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10822650-B2 | Nucleic acid sequencing using tags | Roche Sequencing Solutions, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3728635-A1 | COMPOSITIONS AND METHODS FOR UNIDIRECTIONAL NUCLEIC ACID SEQUENCING | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200294625-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200248250-A1 | NUCLEIC ACID SEQUENCES USING TAGS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3663409-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10622094-B2 | Methods and processes for non-invasive assessment of genetic variations | SEQUENOM, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| EP-2917372-B1 | NUCLEIC ACID SEQUENCING USING TAGS | GENIA TECH INC (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2852680-B1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2019-12-25 | — | — | EP | disclosed |
| WO-2019204585-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190292591-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3540076-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | SPRING BREAK PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3524252-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10376533-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-1994182-B1 | DEGENERATE NUCLEOBASE ANALOGS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-10260093-B2 | Systems and methods for determining genetic data | Genia Technologies, Inc. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20190040468-A1 | Microarray for detection of mutations in beta-globin genes and detection method thereof | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3011051-B1 | METHOD FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2097527-B1 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | QUERDENKER APS (DK) | 2018-08-01 | — | — | EP | disclosed |
| US-9920361-B2 | Methods and compositions for analyzing nucleic acid | SEQUENOM, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180030524-A1 | NUCLEIC ACID SEQUENCING USING TAGS | ROCHE SEQUENCING SOLUTIONS INC (US) | 2018-02-01 | — | — | US | disclosed |
| EP-2915815-B1 | NEW MODIFIED NUCLEIC ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170241948-A1 | NUCLEIC ACID SEQUENCES USING TAGS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-24 | — | — | US | disclosed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20170218360-A1 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | MIRRX THERAPEUTICS A/S (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9677123-B2 | Degenerate nucleobase analogs | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9605309-B2 | Nucleic acid sequencing using tags | Genia Technologies, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-3138928-A1 | SELECTION OF PROBE PAIRS FOR MICROARRAY DETECTION OF MUTATIONS | Mitsubishi Rayon Co. Ltd. (JP) | 2017-03-08 | — | — | EP | disclosed |
| US-9539276-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9453218-B2 | Method for producing a nucleic acid library having at least two adjacent variable codon triplets | FUHRMANN MARKUS (DE) | 2016-09-27 | — | — | US | disclosed |
| EP-3011051-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2748319-B1 | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY HAVING AT LEAST TWO ADJACENT VARIABLE CODON TRIPLETS | FUHRMANN MARKUS (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160016983-A1 | New Modified Nucleic Acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-2956145-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150329864-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9138442-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2917372-A1 | NUCLEIC ACID SEQUENCING USING TAGS | Genia Technologies, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2915815-A1 | NEW MODIFIED NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150184241-A1 | MICROARRAY FOR DETECTION OF MUTATIONS IN beta-GLOBIN GENES AND DETECTION METHOD THEREOF | MITSUBISHI RAYON CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-9040234-B2 | Oligonucleotide analogs as therapeutic agents | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2852680-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| EP-2832863-A1 | MICROARRAY FOR DETECTION OF MUTATIONS IN -GLOBIN GENES AND DETECTION METHOD THEREOF | Mitsubishi Rayon Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20150005176-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. | 2015-01-01 | — | — | US | disclosed |
| WO-2014205401-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20140357531-A1 | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY HAVING AT LEAST TWO ADJACENT VARIABLE CODON TRIPLETS | FUHRMANN MARKUS (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140303032-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Roche Sequencing Solutions, Inc. | 2014-10-09 | — | — | US | disclosed |
| WO-2014127378-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | WO | disclosed |
| EP-2748319-A1 | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY HAVING AT LEAST TWO ADJACENT VARIABLE CODON TRIPLETS | Fuhrmann, Markus (DE) | 2014-07-02 | — | — | EP | disclosed |
| US-20140134616-A1 | NUCLEIC ACID SEQUENCING USING TAGS | Genia Technologies, Inc. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014074727-A1 | NUCLEIC ACID SEQUENCING USING TAGS | Genia Technologies, Inc. (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013177086-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130310260-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | SEQUENOM, INC (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2013124211-A1 | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY HAVING AT LEAST TWO ADJACENT VARIABLE CODON TRIPLETS | FUHRMANN MARKUS (DE) | 2013-08-29 | — | — | WO | disclosed |
| US-20130197066-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2611451-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2013067208-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-8404651-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2012030626-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2271351-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100055798-A1 | Degenerate Nucleobase Analogs | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100021914-A1 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | QUERDENKER APS | 2010-01-28 | — | — | US | disclosed |
| WO-2009146123-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK (US) | 2009-12-03 | — | — | WO | disclosed |
| EP-2097527-A2 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | Querdenker Aps (DK) | 2009-09-09 | — | — | EP | disclosed |
| EP-1373561-B1 | USE OF MASS-MATCHED NUCLEOTIDES IN THE ANALYSIS OF OLIGONUCLEOTIDE MIXTURES AND IN HIGHLY MULTIPLEXED NUCLEIC ACID SEQUENCING | UNIV BOSTON (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1994182-A2 | DEGENERATE NUCLEOBASE ANALOGS | Siemens Healthcare Diagnostics Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008061537-A2 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | QUERDENKER APS (DK) | 2008-05-29 | — | — | WO | disclosed |
| US-7374882-B2 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070259827-A1 | Compositions and methods for enhancing discriminatory RNA interference | UNIVERSITY OF MASSACHUSETTS (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007106690-A2 | DEGENERATE NUCLEOBASE ANALOGS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007087451-A2 | COMPOSITIONS AND METHODS FOR ENHANCING DISCRIMINATORY RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1641942-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | Applera Corporation (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040115665-A1 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040077004-A1 | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and highly multiplexed nucleic acid sequencing | TRUSTEES OF BOSTON UNIVERSITY, THE | 2004-04-22 | — | — | US | disclosed |
| US-6660229-B2 | Synthesizing extension products of the target nucleic acid in the presence of chain terminating nucleotides and mass-matched nucleotides; determining the mass of each extension product; and calculating a mass shift | THE TRUSTEES OF BOSTON UNIVERSITY | 2003-12-09 | — | — | US | disclosed |
| EP-1348035-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | Riken (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002044195-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | RIKEN (JP) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002044195-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | RIKEN (JP) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376533-B2 | Compositions and methods for treating viral infections | SLC10A1, HAVCR2, CYP3A43 | CYP2A6 160/4885CYP1A2 183/4885PSMD14 3785/4885 |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | CYP2A6 160/4885CYP1A2 183/4885PSMD14 3785/4885 |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | CYP2A6 160/4885CYP1A2 183/4885PSMD14 3785/4885 |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | CYP2A6 3798/4885CYP1A2 4414/4885PSMD14 4199/4885 |
| US-20160016983-A1 | New Modified Nucleic Acid | RNGTT, RNASEH1, RNASE1 | CYP2A6 2623/4885CYP1A2 4596/4885PSMD14 2905/4885 |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | DTYMK, UNG, TPR | CYP2A6 4838/4885CYP1A2 4876/4885PSMD14 3758/4885 |
| US-20130197066-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | CYP2A6 160/4885CYP1A2 183/4885PSMD14 3785/4885 |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | CYP2A6 282/4885CYP1A2 161/4885PSMD14 4057/4885 |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | TLR3, TLR5, TLR9 | CYP2A6 4287/4885CYP1A2 4568/4885PSMD14 4214/4885 |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | CYP2A6 3293/4885CYP1A2 4663/4885PSMD14 2920/4885 |
| US-20250388955-A1 | METHYLATION DETECTION WITH A NON-NATURAL/UNNATURAL BASE | ALPG, MPG, OGG1 | CYP2A6 3594/4885CYP1A2 4550/4885PSMD14 3478/4885 |
| US-20100021914-A1 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | RNASEH1, RNASE1, RNASEL | CYP2A6 3821/4885CYP1A2 4626/4885PSMD14 1488/4885 |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | CYP2A6 160/4885CYP1A2 183/4885PSMD14 3785/4885 |
| US-20260110026-A1 | METHODS FOR PROPAGATING AND MAPPING LOCATION OF NON-NATURAL BASES | UNG, DNMT1, TET1 | CYP2A6 2168/4885CYP1A2 2552/4885PSMD14 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.